Valuation dashboard for aTyr Pharma, Inc. (ATYR) with P/E N/A, P/B 0.72, EV/EBITDA -1.02 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2.
Analysis Summary
aTyr Pharma, Inc. reported revenue of $190000 in the most recent fiscal year, growing at a 5-year CAGR of -55.1%.
Trailing-twelve-month margins: gross margin -117.5%, operating margin -336.1%, net margin -320.0%.
At the current price of $0.38, ATYR has negative trailing earnings (P/E not meaningful) and an ROE of -109.84%. Market capitalisation stands at $38M.
Balance sheet quality for ATYR: current ratio of 5.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.72 |
| EV / EBITDA | -1.02 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ATYR | aTyr Pharma, Inc. | $38M | 0.72 | -109.8% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.38 |
| Market Cap | $38M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -109.84% |
| Return on Invested Capital | -96.45% |
| Return on Assets | -78.71% |
| Gross Margin | -11754.74% |
| Operating Margin | -33609.47% |
| Net Margin | -32003.68% |
Related companies: ACRV · ALXO · CAMP · DTIL · HYFT · MGX · QNCX
Explore sector: Healthcare · Biotechnology
More sections of ATYR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks